EP.12H.09 Phase 1b/2a Study of ATR Inhibitor Tuvusertib + Anti-PD-1 Cemiplimab in Patients with Advanced Non-Squamous NSCLC
Natalie I. Vokes(The University of Texas MD Anderson Cancer Center), L.C. Villaruz(UPMC Hillman Cancer Center), Jhanelle E. Gray(Moffitt Cancer Center), T. Owonikoko(University of Pittsburgh), R. Hallwachs(Merck KGaA, Darmstadt (Germany)), Camilo Moulin(Merck KGaA, Darmstadt (Germany)), Ioannis Gounaris(Novartis (Switzerland)), Linda Pudelko(Merck KGaA, Darmstadt (Germany)), Nobuyuki Yamamoto(Wakayama Medical University), Federico Cappuzzo(Ospedale di Livorno), Jin‐Hyoung Kang(The Catholic University of Korea Seoul St. Mary's Hospital), Hiroshi Ishii(Chiba Cancer Center), Jatinder Kaur Mukker(Merck Serono S.p.A. (Italy)), S.-H. Lee(Samsung Medical Center), Anna Coenen-Stass(Merck KGaA, Darmstadt (Germany)), L. Paz-Ares(Hospital Universitario 12 De Octubre), Barbara Sarholz(Merck KGaA, Darmstadt (Germany)), Ryo Ariyasu(The Cancer Institute Hospital)
Cited by 0
Related Papers
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k